

# Scancell Holdings PLC

13:19 01 Jul 2019

## Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

Scancell Holdings PLC (LON:SCLP) shares advanced on Monday after the firm provided an upbeat half-year update on progress for its various clinical studies.

The company will begin recruiting patients with advanced melanoma for UK Phase 2 clinical trials of its SCIB1 novel cancer immunotherapy in the coming weeks, following regulatory approval in April.

**WATCH:** Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

In order to begin the study in the US there are talks ongoing with the regulator about administering the drugs using the TriGrid electroporation delivery system.

Saying that he looked forward to updating the market on the US arm of this trial and patient recruitment in due course, Scancell's chief executive Dr Cliff Holloway summed up the six-month period as "busy and productive".

Progress towards initiating a Phase 1/2 clinical trial for Modi-1, the first cancer treatment from the company's Moditope platform, has seen formulation work "well underway" to produce the final product for clinical testing and initiation of the preclinical toxicity testing programme.

On the SCIB2 ImmunoBody vaccine, there was no fresh news since May's milestone joint update with Cancer Research UK that showed the potency of immune responses and prolonged survival in pre-clinical trials ahead of moving into the clinic with patients suffering from solid tumours.

Holloway also hailed the establishment of a clinical advisory board and the £3.9mIn new investment from Vulpes Life Sciences in June, saying the investment "not only strengthens our cash position, but provides a ringing endorsement of Scancell's future potential", as well as adding insight to the board.

In afternoon trading, shares in Scancell were 5.9% higher at 7.15p.

-- Adds share price --

**Price:** 7.1

**Market Cap:** £33.04 m

### 1 Year Share Price Graph



January 2019 July 2019 January 2020

### Share Information

**Code:** SCLP

**Listing:** LSE

52 week	High	Low
	10	3

**Sector:** Pharma & Biotech

**Website:** [www.scancell.co.uk](http://www.scancell.co.uk)

### Company Synopsis:

*Cancer remains one of the world's most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body's own natural defence mechanism - the immune system. Scancell's mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).